Sign Out
Pantoprazole is not indicated for mild gastrointestinal complaints, such as nervous dyspepsia. In the case of combination therapy, the summaries of product characteristics of the respective drugs should be observed. Prior to treatment the possibility of malignancy of gastric ulcer or a malignant disease of the esophagus should be excluded as the treatment with Pantoprazole may alleviate the symptoms of malignant ulcers and can thus delay diagnosis. Diagnosis of reflux esophagitis should be confirmed by endoscopy.
EC caplet: To date there has been no experience with treatment in children.
In patient with Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions requiring long-term treatment, Pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered if respective clinical symptoms are observed.
Powd for inj: Impaired renal function and severe liver impairment (reduce daily dose to 20 mg). Monitor liver enzymes during therapy.
Effect on the ability to drive and to use machines: There are no known effects on the ability to drive and use of machines.
Use in Pregnancy and lactation: Clinical experience in pregnant women is limited. In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg. There is no information on the excretion of Pantoprazole into human breast milk. Pantoprazole caplets should only be used when the benefit to the mother is considered greater than the potential risk to the foetus/baby.
